Sage Therapeutics (SAGE) PT Lowered to $84 at RBC Capital Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
May 4, 2021 6:30 AM EDTCompany on-track to initiate placebo-controlled Phase 2 trial with SAGE-718 in Huntingtons disease in late 2021, as the target for the first indication for SAGE-718, following encouraging signals in Phase 1 data
PARADIGM Study with SAGE-718 showed improved performance from baseline on multiple tests of executive function over 14 days of treatment in patients with Parkinsons disease cognitive impairment, further supporting development in disorders associated with cognitive dysfunction
Positive topline data from Phase 2 KINETIC Study showed statistically significant reduction in tremor score with SAGE-324 compared to placebo at Day 29 in adults... More
